We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Quality of Life Intermittent Catheter Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01523743
Recruitment Status : Completed
First Posted : February 1, 2012
Results First Posted : May 22, 2014
Last Update Posted : September 30, 2016
Sponsor:
Information provided by (Responsible Party):

Study Description
Brief Summary:
The purpose of this study is to compare compact intermittent catheters with standard coated intermittent catheters with regard to quality of life, using the Intermittent Self-Catheterisation Quality of life Measure.

Condition or disease Intervention/treatment Phase
Neurogenic Bladder Dysfunction Nos Device: SpeediCath Compact Device: Standard care Phase 4

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 125 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Supportive Care
Official Title: Quality of Life Intermittent Catheter Study - A Prospective, Randomized, Cross-over, Multicenter Study Comparing Quality of Life Using Compact Versus Standard Urinary Intermittent Catheters
Study Start Date : November 2011
Primary Completion Date : April 2012
Study Completion Date : May 2012
Arms and Interventions

Arm Intervention/treatment
Experimental: Compact catheter
Compact intermittent catheter
Device: SpeediCath Compact
The SpeediCath Compact intermittent catheter is used for single-use urinary bladder drainage through the urethra.
Other Names:
  • SpeediCath®Compact Male, for male participants
  • SpeediCath®Compact Female, for female participants
Active Comparator: Standard Care
Standard Care: Coated intermittent catheter normally used by subject
Device: Standard care
The coated intermittent catheter normally used by subject


Outcome Measures

Primary Outcome Measures :
  1. Quality of Life (0-100 Point) [ Time Frame: 6 weeks ]
    Difference in intermittent self-catheterisation quality of life measure, comparing compact versus standard urinary intermittent catheters The range of the scale is 0-100 where a high score indicating a high level of Quality of Life.


Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Is at least 18 years of age
  • Has given written informed consent
  • Has neurogenic bladder dysfunction
  • Has used coated intermittent catheter as primarily bladder emptying method for at least 6 months
  • Is able to self-catheterise
  • Is able to use SpeediCath® compact catheters
  • If spinal cord injury subject, injury must have occurred more than 12 months ago
  • Covered by Social security system

Exclusion Criteria:

  • Has used SpeediCath® compact catheters (not including screening for this investigation)
  • Is admitted to rehabilitation centre
  • Subjects using primarily catheter sets
  • Is pregnant or breast-feeding
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01523743


Locations
Denmark
PrivatHospitalet Danmark, privat hospital,
Charlottenlund, Denmark
Rigshospitalet, Urology clinic,
Copenhagen, Denmark
CCBR Vejle, Clinical research site,
Vejle, Denmark
France
Hôpital Tenon, Neuro-Urology and perineal explorations department,
Paris, Cedex 20, France
Hôpital Raymond Poincaré, Urology clinic
Garches, France, 92350
Hôpital Léon Berard, Rehabilitation clinic,
Hyères cedex, France
Hôpital Henry Gabrielle, Urology clinic,
Saint Genis Laval, France
Germany
University Heidelberg, Neuro-Urology clinic,
Heidelberg, Germany
Norway
St. Olavs Hospital HF, Neurologi clinic,
Trondheim, Norway
Sweden
Gävle sjukhus, Urology clinic,
Gävle, Sweden
Rehab Station Stockholm,
Stockholm, Sweden
Sponsors and Collaborators
Coloplast A/S
Investigators
Principal Investigator: Emmanuel Chartier-Kastler, Proff Hôpital Raymond poincarè, Service d'Urologie, Garches, France
More Information

Responsible Party: Coloplast A/S
ClinicalTrials.gov Identifier: NCT01523743     History of Changes
Other Study ID Numbers: CP220
First Posted: February 1, 2012    Key Record Dates
Results First Posted: May 22, 2014
Last Update Posted: September 30, 2016
Last Verified: August 2016

Additional relevant MeSH terms:
Urinary Bladder, Neurogenic
Neurologic Manifestations
Nervous System Diseases
Urinary Bladder Diseases
Urologic Diseases
Signs and Symptoms